Chemistry: analytical and immunological testing – Tracers or tags
Reexamination Certificate
2005-02-03
2009-11-24
Siefke, Sam P (Department: 1797)
Chemistry: analytical and immunological testing
Tracers or tags
C435S069100, C435S366000, C435S320100
Reexamination Certificate
active
07622303
ABSTRACT:
In general, the invention is directed to systems and techniques for assessing a risk of ventricular tachyarrhythmia in a patient by measuring one or more biochemical markers that reflect the health of a patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more biomarkers. Based upon the results of the tests, the patient's risk of ventricular tachyarrhythmia may be assessed. When the patient is found to be at risk, the patient may receive an implantable medical device or drug therapy to address the risk.
REFERENCES:
patent: 5018067 (1991-05-01), Mohlenbrock
patent: 5437285 (1995-08-01), Verrier
patent: 6099469 (2000-08-01), Armstrong et al.
patent: 6210976 (2001-04-01), Sabbadini
patent: 6274332 (2001-08-01), Keating
patent: 6306087 (2001-10-01), Barnhill
patent: 6368823 (2002-04-01), Brill et al.
patent: 6432644 (2002-08-01), Keating
patent: 6458542 (2002-10-01), George, Jr. et al.
patent: 6500630 (2002-12-01), Conover
patent: 6571129 (2003-05-01), Schaldach
patent: 6597952 (2003-07-01), Mika
patent: 6647341 (2003-11-01), Golub
patent: 7208273 (2007-04-01), Keating
patent: 2002/0049772 (2002-04-01), Rienhoff, Jr.
patent: 2002/0059030 (2002-05-01), Otworth et al.
patent: 2002/0076809 (2002-06-01), Steinmeyer et al.
patent: 2002/0077470 (2002-06-01), Walker
patent: 2002/0086297 (2002-07-01), Siffert
patent: 2002/0115073 (2002-08-01), Papadopoulos
patent: 2002/0155539 (2002-10-01), Ruben et al.
patent: 2002/0165161 (2002-11-01), Allison
patent: 2002/0182599 (2002-12-01), Fishman
patent: 2003/0004402 (2003-01-01), Hitt
patent: 2003/0096782 (2003-05-01), Bristow
patent: 2003/0108924 (2003-06-01), George, Jr. et al.
patent: 2003/0162192 (2003-08-01), Sotos
patent: 2003/0175795 (2003-09-01), Walker
patent: 2003/0198970 (2003-10-01), Roberts
patent: 2003/0228565 (2003-12-01), Oestreicher
patent: 2003/0235838 (2003-12-01), Keating
patent: 0842475 (1997-02-01), None
patent: 0 721 786 (1998-03-01), None
patent: 1100825 (2000-02-01), None
patent: 1176197 (2002-01-01), None
patent: 1 480 251 (2004-11-01), None
patent: 95/15116 (1995-06-01), None
patent: 96/28537 (1996-09-01), None
patent: 98/09226 (1998-03-01), None
patent: WO 99/27140 (1999-03-01), None
patent: 99/51778 (1999-10-01), None
patent: WO 99/51778 (1999-10-01), None
patent: WO 99/67628 (1999-12-01), None
patent: 01/81895 (2001-11-01), None
patent: 01/92567 (2001-12-01), None
patent: WO 02/052033 (2002-07-01), None
patent: 02/086447 (2002-10-01), None
patent: WO 03/002757 (2003-01-01), None
patent: WO 03/006687 (2003-01-01), None
patent: 03/040407 (2003-05-01), None
patent: WO 2004/005931 (2004-01-01), None
Arrell et al., Cardiovascular Proteomics, Evolution and Potential, Circulation Research, 88:763-773, 2001.
Diamandis, Eleftherios P., Proteomic Patterns in Biological Fluids: Do They Represent the Future of Cancer Diagnostics?, Clinical Chemistry, 49(8):1272-1278, 2003.
Kiernan et al., Comparative Urine Protein Phenotyping Using Mass Spectrometric Immunoassay, Journal of Proeteome Research.
Petricoin, Emanuel F., III., et al., Use of Proteomic Patterns in Serum to Identify Ovarian Cancer, The Lancet, 359:572-577, 2002.
Rubenstein, Ken, Ph.D., Post-Genomic Biomarkers: Revolutionizing Drug Development and Diagnostics, D&MD Publications, Report #9129, Sep. 2003.
Danne, et al., Prognostic Implications of Elevated Whole Blood Choline Levels in Acute Coronary Syndromes, American Journal of Cardiology, 91:1060-1067, 2003.
Issaq, et al., The SELDI-TOF MS Approach to Proteomics: Protein Profiling and Biomarker Identification, Biochemical and Biophysical Research Communications 292:587-592, 2002.
“‘Peptide’ may help predict early heart disease,” CNN.com, p. 1-3 (Feb. 12, 2004).
Moss, AJ et al., “Increased Risk of Arrhythmic Events in Long-QT Syndrome with Mutations in the Pore Region of the Human Ether-a-go-go-Related Gene Potassium Channel,”Circulation, vol. 105, No. 7, p. 794-799 (Feb. 19, 2002).
Fananapazir, et al., Genotype-Phenotype Correlations in Hypertrophic Cardiomyopathy: Insights Provided by Comparisons of Kindreds with Distinct and Identical Beta-myosin Heavy Chain Gene Mutations, Circulation, 1994; 89 (1): 22-32.
Samani, et al., A Meta-analysis of the Association of the Deletion Allele of the Angiotensin-Converting Enzyme Gene with Myocardial Infarction, Circulation, 1996; 94: 708-12.
Aronsky, et al., An Integrated Decision Support System for Diagnosing and Managing Patients with Community-Acquired Pneumonia, Proc. AMIA Symp., 1999; 197-201.
Colombet, et al., Decision Aids for Triage of Patients with Chest Pain: A Systematic Review of Field Evaluation Studies, Proc. AMIA Symp., 1999; 231-35.
Jouven, et al., Predicting Sudden Death in the Population: The Paris Prospective Study I, Circulation, 1999; 99: 1978-83.
Dunn, Studying Heart Disease Using the Proteomic Approach, Drug Discovery Today, Feb. 1, 2000; 5(2): 76-84.
Jouven et al., Circulating Nonesterified Fatty Acid Level as a Predictive Risk Factor for Sudden Death in the Population, Circulation, 2001; 101: 756-61.
Iwasa, et al., Multiple Single-Nucleotide Polymorphisms (SNPS) in the Japanese Population in Six Candidate Genes for Long QT Syndrome, J. Hum. Genet., 2001; 46: 158-62.
Christodoulides, et al., A Microchip-Based Multianalyte Assay System for the Assessment of Cardiac Risk, Analytical Chemistry, 2002; 74(13): 3030-36.
Iwasa, et al., Twenty Single-nucleotide Polymorphisms in Four Genes Encoding Cardiac Ion Channels, J. Hum. Genet., 2002; 47(4): 208-12.
Hirschhorn, et al., A Comprehensive Review of Genetic Association Studies, Genetics in Medicine, 2002; 4(2): 45-61.
Frank-Hansen, et al., Mutations in the Genes KCND2 and KCND3 Encoding the Ion-Channels Conducting the Cardiac Transient Outward Current (ITO) is not a Frequent Cause of Long QT Syndrome, Am. J. Hum. Genet., 2002; 71(4 Supp.): 521.
Hegele, SNP Judgments and Freedom of Association, Arteriosclerosis, Thrombosis, and Vascular Biology, 2002; 22: 1058-61.
Splawski, et al., Variant of SCN5A Sodium Channel Implicated in Risk of Cardiac Arrhythmia, Science, Aug. 23, 2002, 297:1333-36.
NCBI Database SNP [Online], Sep. 7, 2000,refSNP ID: ss1472059.
NCBI Database SNP [Online], Oct. 20, 2000, refSNP ID: rs1538389; & NCBI Database SNP [Online], Oct. 20, 2000, refSNP ID: ss2379946.
NCBI Database SNP [Online], refSNP ID: rs1808973; & NCBI Database SNP [Online], Jan. 2, 2001, refSNP ID: ss2672972.
NCBI Database SNP [Online], refSNP ID: rs730022 & NCBI Database SNP [Online], Sep. 6, 2000, refSNP ID: ss74946.
Dhar et al., Prognostic significance of metastatic lymph node size in patients with gastric cancer, British J. of Surgery, 2003; 90: 1522-30.
Kuzuya et al., Report of the Committee on the classification and diagnostic criteria of diabetes mellitus, Diabetes Res. and Clin. Practice, 2002; 55: 65-85.
Dearking Amy C.
Olson Walter H.
Robinson Timothy H.
Sharma Vinod
Soykan Orhan
Hahn Roger C.
Hahn & Voight PLLC
Medtronic Inc.
Siefke Sam P
LandOfFree
Methods for identifying patients at risk for life... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying patients at risk for life..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying patients at risk for life... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4141856